Nooglutyl (Nooglutil)
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Our verdict NOT-RELEVANT LOW
Mechanism is plausible but the entire human evidence base is Russian-only — Voronina / Seredenin / Zakusov Institute lineage — with no Western RCTs, no Western case series, no English-language pharmacology beyond translated abstracts. For Dylan-archetype the compound would be mechanism-redundant on top of Semax + Adamax + Bromantane (planned) + modafinil + the V4 base; sourcing is harder than noopept (less common at RUPharma/CosmicNootropic), data is sparser than noopept, and the marginal contribution is unclear. Verdict would upgrade to WATCH-LIST only if (i) a Russian-language literature dive surfaces meaningful signal beyond the Zakusov ecosystem, or (ii) Adamax/Semax/Bromantane fail to deliver and a different glutamate-axis compound is wanted that noopept cannot fill.
▸ Decision matrix by user profile Per-archetype
| Archetype | Verdict | Rationale |
|---|---|---|
Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype) | NOT-RELEVANT | Mechanism is plausible but the role is fully covered by compounds with stronger evidence already on or near Dylan's stack — noopept (better-evidenced AMPA + BDNF route), semax + adamax (better-evidenced neurotrophic route), bromantane (DA arm), modafinil (wakefulness). Adding nooglutyl on top of any of these is mechanism-redundant. As a *substitute* for noopept it loses on every dimension (sparser data, harder sourcing, no clear advantage). Do not add. |
Dylan20-30, brain-priority, NOT already running other Russian nootropics | SKIP-FOR-NOW | Even in this profile, noopept is strictly better — same general mechanism class, much stronger evidence base, easier sourcing, lower cost. Nooglutyl has no profile niche in which it dominates noopept. |
30-50, executive maintenance | SKIP-FOR-NOW | Same logic. |
50+, mild cognitive decline, vascular component | MAYBE WATCH-LIST | This is the one profile where nooglutyl has its strongest case — Russian Rx indication is specifically cerebrovascular insufficiency / vascular cognitive impairment, and the 5-hydroxynicotinoyl vascular component theoretically adds something noopept doesn't have. Even here, the data thinness and sourcing difficulty argue for noopept (or pyrrolidone derivatives, or established Western interventions for vascular cognitive impairment) instead. |
Anxiety-prone | NOT-RELEVANT | No anxiolytic-specific positioning; Selank or noopept are better picks. |
High athletic load, tested status | NOT-RELEVANT | Not WADA-banned per available data, but role doesn't fit athletic profile distinctively. |
Sleep-disordered | NOT-RELEVANT | No sleep-relevant mechanism. |
Recovery-focused (post-injury, post-illness, post-concussion) | MAYBE WATCH-LIST | Neuroprotective framing could apply, but Cerebrolysin + Semax + noopept already cover this territory with better evidence. |
Strength/anabolic-focused | NOT-RELEVANT | No anabolic mechanism. |
- Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)NOT-RELEVANT
Mechanism is plausible but the role is fully covered by compounds with stronger evidence already on or near Dylan's stack — noopept (better-evidenced AMPA + BDNF route), semax + adamax (better-evidenced neurotrophic route), bromantane (DA arm), modafinil (wakefulness). Adding nooglutyl on top of any of these is mechanism-redundant. As a *substitute* for noopept it loses on every dimension (sparser data, harder sourcing, no clear advantage). Do not add.
- Dylan20-30, brain-priority, NOT already running other Russian nootropicsSKIP-FOR-NOW
Even in this profile, noopept is strictly better — same general mechanism class, much stronger evidence base, easier sourcing, lower cost. Nooglutyl has no profile niche in which it dominates noopept.
- 30-50, executive maintenanceSKIP-FOR-NOW
Same logic.
- 50+, mild cognitive decline, vascular componentMAYBE WATCH-LIST
This is the one profile where nooglutyl has its strongest case — Russian Rx indication is specifically cerebrovascular insufficiency / vascular cognitive impairment, and the 5-hydroxynicotinoyl vascular component theoretically adds something noopept doesn't have. Even here, the data thinness and sourcing difficulty argue for noopept (or pyrrolidone derivatives, or established Western interventions for vascular cognitive impairment) instead.
- Anxiety-proneNOT-RELEVANT
No anxiolytic-specific positioning; Selank or noopept are better picks.
- High athletic load, tested statusNOT-RELEVANT
Not WADA-banned per available data, but role doesn't fit athletic profile distinctively.
- Sleep-disorderedNOT-RELEVANT
No sleep-relevant mechanism.
- Recovery-focused (post-injury, post-illness, post-concussion)MAYBE WATCH-LIST
Neuroprotective framing could apply, but Cerebrolysin + Semax + noopept already cover this territory with better evidence.
- Strength/anabolic-focusedNOT-RELEVANT
No anabolic mechanism.
▸ Subjective experience (deep)
Sparse data. Russian clinical descriptors emphasize "improvement of attention, memory, and emotional-volitional functions" in cognitive impairment populations — the same generic descriptors used for noopept, piracetam, and most Russian nootropics. No detailed phenomenological characterization in English-language sources. Biohacker forum reports are rare and inconsistent — too few signal points to generate a meaningful subjective profile.
What can be said: based on the AMPA/NMDA-modulation mechanism, the expected subjective signature would resemble a milder noopept or aniracetam — modest cognitive clarity, limited stim component, possibly mild anxiolytic edge. This is mechanism-based extrapolation, not user-report-based characterization.
▸ Tolerance + cycling deep dive
- Tolerance buildup: Not well-characterized. Mechanism (AMPA/NMDA modulation) suggests modest tolerance is plausible. Russian cycling protocols match generic Russian nootropic practice (1–2 month courses, 1 month off).
- Cross-tolerance: Likely partial overlap with noopept, racetams (shared AMPA mechanism). Not characterized empirically.
- Recommended cycle: 1–2 months on, 1 month off (Russian clinical pattern). Daily continuous use beyond 2 months has no published support.
▸ Stacking deep dive
Synergistic with
- Citicoline / Alpha-GPC (Dylan's V4): Generic choline cofactor for any AMPA/cholinergic-adjacent nootropic. Probably useful but not specifically studied with nooglutyl.
- Cerebrolysin (Dylan's V5 quarterly): Different mechanism (peptide trophic) — theoretical synergy on the neuroprotective axis. No specific Russian co-prescription data.
Avoid stacking with (or caution)
- Noopept: Significant mechanism overlap (AMPA modulation + neuroprotective framing). Stacking the two is mechanism-redundant. Pick one.
- Multiple racetams simultaneously: Same logic — partial AMPA + cholinergic mechanism overlap, diminishing returns.
- NMDA antagonists / dissociatives: Theoretical pharmacological antagonism with the NMDA-modulator arm. Not empirically studied.
Neutral / safe co-administration
Magnesium, creatine, fish oil, vitamin D3, NAC, rhodiola, theanine, caffeine — Dylan's V4 daily core would be compatible. Modafinil, bromantane, semax — different primary mechanisms, no documented incompatibility but stacking mechanism-redundant compounds (noopept + nooglutyl + adamax + semax simultaneously) is poor stack design regardless of any individual safety profile.
▸ Drug interactions deep dive
Limited published data. Glutamate-axis compounds theoretically interact with NMDA antagonists (memantine, ketamine) and AMPA potentiators. CYP interactions not well-characterized. Treat as low-data compound — assume interaction risk is not zero, just unmeasured. Discontinue 1–2 weeks pre-surgery as a conservative default.
▸ Pharmacogenomics
No published data on response by genotype. Theoretically, BDNF Val66Met and APOE4 status might modulate response (as for any glutamatergic/neurotrophic-axis compound) but this is speculative.
▸ Sourcing deep dive
| Path | Vendor | Cost | Reliability | Notes |
|---|---|---|---|---|
| Gray-market (Russian) | RUPharma | ~$30–50 / 30-day supply (when in stock) | Medium — limited stock, intermittent availability | Far less commonly stocked than noopept, semax, bromantane. Compound is niche even within the Russian nootropic export market. |
| Gray-market (Russian) | CosmicNootropic | ~$30–50 / 30-day supply (when in stock) | Medium — same intermittent availability profile | Backup option; same Russian pharmaceutical-grade source. |
| Research-chem (US) | Various | Variable | Low | Effectively not a research-chem-market compound. Compound is too niche for the mainstream research-chem vendor ecosystem. |
| Russian pharmacy (in-country) | N/A | Russian Rx pricing | High (in-country) | Not a realistic path for Dylan. |
Sourcing reality 2026: Hard. Nooglutyl is substantially less commonly stocked than other Russian nootropics — RUPharma and CosmicNootropic carry it only intermittently. Even when in stock, the price-per-effective-dose is higher than noopept, the evidence base is thinner, and the role on Dylan's stack is redundant. Combination of harder sourcing + sparser data + redundant mechanism is the central reason for the NOT-RELEVANT verdict.
▸ Biomarkers to track (deep)
If trialed (not recommended for Dylan): subjective cognitive output rating, headache frequency, sleep onset, anxiety. CBC + LFTs at 4-week mark for any 1–2 month cycle. No nooglutyl-specific biomarkers exist — generic nootropic biomarker panel applies.
▸ Controversies / open debates Live debate
1. Russian-only evidence — strongest version of the concern. Where noopept and bromantane have a moderately substantial Russian evidence base and at least some Western secondary literature, nooglutyl has a thin Russian evidence base and almost no Western secondary literature. The compound is genuinely obscure even by Russian-nootropic standards.
2. Mechanism plausibility vs evidence quality mismatch. The claimed dual AMPA + NMDA modulation + cerebrovascular component is a coherent mechanistic story — arguably more coherent than noopept's "1000× piracetam" framing. But mechanism plausibility is not population-level efficacy data. A compound can have a beautiful mechanism story and still not work meaningfully in real humans — this is the main reason Western EBM weights mechanism less heavily than Russian neuropharmacology does.
3. CMP/PMP balance framing — Russian-specific concept with limited Western mapping. "Balance of cerebral metabolic processes and plasticity-mediating processes" is a Russian-neuropharmacology framing that doesn't map cleanly onto Western mechanistic categories. Western readers should treat this as institutional vocabulary, not as a separately-validated mechanistic insight.
4. Why hasn't nooglutyl caught on in the biohacker community? This is itself diagnostic. Compounds with real signal — noopept, semax, bromantane — develop substantial gray-market biohacker followings. Compounds without real signal stay obscure. Nooglutyl has had ~25+ years to escape the Zakusov ecosystem and hasn't. This is weak negative evidence.
5. Niche cerebrovascular fit — does the niacin-arm differentiate it usefully? Theoretically yes — for vascular cognitive impairment, the 5-hydroxynicotinoyl moiety could in principle add something noopept lacks. In practice, no Russian or Western trial has cleanly demonstrated this differentiation. The mechanism is plausible but the differentiated benefit is unproven.
▸ Verdict change log
- 2026-05-06 — Initial verdict: NOT-RELEVANT, LOW confidence. For Dylan-archetype: obscure Russian glutamate-axis nootropic with plausible mechanism (AMPA + NMDA modulation + cerebrovascular component) but extraordinarily thin English-language evidence base, harder sourcing than noopept, and mechanism-redundant role on Dylan's V5 stack. Verdict would upgrade to WATCH-LIST only if a Russian-language literature dive surfaces meaningful signal beyond the Zakusov ecosystem, or if Dylan's planned Russian peptide stack (Semax + Adamax + Bromantane) underperforms expectations and a different glutamate-axis compound is wanted. Plan: do NOT add. Park the file and revisit only if Russian-language deep research is later prioritized for the wiki.
▸ Open questions / gaps Open
- Does any Russian-language literature outside the Zakusov ecosystem provide independent signal? Untested in this pass — would require Russian-language deep dive.
- What is the actual subjective phenomenology of nooglutyl in healthy adults? Almost no biohacker reports exist to characterize this.
- Does the cerebrovascular niacin-arm meaningfully differentiate clinical effect from noopept/piracetam? Mechanistically plausible, empirically unproven.
- Pharmacokinetics in detail? Largely uncharacterized in English-language sources.
- Real-world tolerance, long-term safety, drug interactions? Effectively unstudied at population scale.
- Why has the compound stayed obscure? Could be (a) genuine lack of differentiated benefit, (b) sourcing/marketing factors, (c) mechanism story didn't translate well — likely some mix.
▸ Sources (full, with our context)
- Voronina TA et al. — Zakusov Institute nooglutyl pharmacology papers — foundational animal pharmacology, Russian-language primary literature with English abstracts.
- Seredenin SB et al. — Zakusov Institute conceptual framing of CMP/PMP balance and Russian nootropic class — institutional context for the Russian nootropic taxonomy.
- Russian Pharmacological Committee — Nooglutyl marketing authorization dossier — basis for Russian Rx authorization in cerebrovascular insufficiency.
- RUPharma — Nooglutyl product page (when in stock) — primary gray-market source, intermittent availability.
- CosmicNootropic — Nooglutyl product page (when in stock) — backup gray-market source.
- r/Nootropics — sparse nooglutyl threads — limited biohacker discussion, mostly mechanism speculation.
- Note: Western secondary literature (Examine.com, Nootropics Expert, Wikipedia substantive entry) is essentially absent for this compound — itself a meaningful negative signal.